Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Niraparib in Combination With Anlotinib Based on CA 125 Level in Newly Diagnosed Ovarian Cancer: A Open-label, Single Arm, Prospective Phase II Trial

NCT05311579 is registered in ClinicalTrials.gov with Lei Li as lead sponsor.

NCT NCT05311579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05311579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Niraparib in Combination With Anlotinib Based on CA 125 Level in Newly Diagnosed Ovarian Cancer: A Open-label, Single Arm, Prospective Phase II Trial
Lead sponsor
Lei Li
Phase
Phase 2
Overall status
Unknown status
Start date
March 27, 2022
Completion date
March 27, 2024
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adverse events, anlotinib, ca125, chemotherapy, niraparib, ovarian carcinoma, recurrent ovarian cancer, survival outcomes, targeted therapy